Trials / Terminated
TerminatedNCT02102594
Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Charite University, Berlin, Germany · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this pilot study is to investigate the application of proteasome inhibitor Bortezomib (Velcade®, approved for therapy of multiple myeloma) in patients with therapy-refractory antibody-mediated autoimmune diseases. The investigators hypothesis is that the proteasome inhibition will lead to reduced antibody titers and improved clinical outcome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bortezomib | Bortezomib will be subcutaneously applicated in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle. |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2019-08-30
- Completion
- 2019-08-30
- First posted
- 2014-04-03
- Last updated
- 2019-12-03
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT02102594. Inclusion in this directory is not an endorsement.